PortalPublikationenBRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatme...

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study

Standard

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. / Fasching, P. A.; Loibl, S.; Hu, C.; Hart, S. N.; Shimelis, H.; Moore, R.; Schem, C.; Tesch, H.; Untch, M.; Hilfrich, J.; Rezai, M.; Gerber, B.; Costa, S. D.; Blohmer, J. U.; Fehm, T.; Huober, J.; Liedtke, C.; Weinshilboum, R. M.; Wang, L.; Ingle, J. N.; Muller, V.; Nekljudova, V.; Weber, K. E.; Rack, B.; Rubner, M.; von Minckwitz, G.; Couch, F. J.

in: J CLIN ONCOL, Jahrgang 36, Nr. 22, 01.08.2018, S. 2281-2287.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Fasching, PA, Loibl, S, Hu, C, Hart, SN, Shimelis, H, Moore, R, Schem, C, Tesch, H, Untch, M, Hilfrich, J, Rezai, M, Gerber, B, Costa, SD, Blohmer, JU, Fehm, T, Huober, J, Liedtke, C, Weinshilboum, RM, Wang, L, Ingle, JN, Muller, V, Nekljudova, V, Weber, KE, Rack, B, Rubner, M, von Minckwitz, G & Couch, FJ 2018, 'BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study', J CLIN ONCOL, Jg. 36, Nr. 22, S. 2281-2287. https://doi.org/10.1200/JCO.2017.77.2285

APA

Fasching, P. A., Loibl, S., Hu, C., Hart, S. N., Shimelis, H., Moore, R., Schem, C., Tesch, H., Untch, M., Hilfrich, J., Rezai, M., Gerber, B., Costa, S. D., Blohmer, J. U., Fehm, T., Huober, J., Liedtke, C., Weinshilboum, R. M., Wang, L., ... Couch, F. J. (2018). BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J CLIN ONCOL, 36(22), 2281-2287. https://doi.org/10.1200/JCO.2017.77.2285

Vancouver

Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R et al. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J CLIN ONCOL. 2018 Aug 1;36(22):2281-2287. https://doi.org/10.1200/JCO.2017.77.2285

Bibtex

@article{f1a10cae4fa14ec09e0e41609f8ea8e9,
title = "BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study",
abstract = "Purpose BRCA1/2 mutations are frequent in patients with triple-negative breast cancer (TNBC). These patients are often treated with primary systemic chemotherapy. The aim of this study was to analyze the effects of BRCA1/2 mutations on pathologic complete response (pCR) and disease-free survival (DFS) in a cohort of patients with TNBC treated with anthracycline and taxane-containing chemotherapy, with or without bevacizumab. Patients and Methods Germline DNA was sequenced to identify mutations in BRCA1 and BRCA2 in 493 patients with TNBC from the GeparQuinto study. The pCR rates were compared in patients with and without mutation, as well as in patients treated with and without bevacizumab. In addition, the influence of BRCA1/2 mutation status and pCR status on DFS was evaluated relative to treatment. Results BRCA1/2 mutations were detected in 18.3% of patients with TNBC. Overall, patients with mutations had a pCR rate of 50%, compared with 31.5% in patients without a mutation (odds ratio [OR], 2.17; 95% CI, 1.37 to 3.46; P = .001). The pCR rate among patients treated with bevacizumab was 61.5% for BRCA1/2 mutation carriers and 35.6% for those without mutations (OR, 2.90; 95% CI, 1.43 to 5.89; P = .004). pCR was a strong predictor of DFS for patients without BRCA1/2 mutations (hazard ratio, 0.18; 95% CI, 0.11 to 0.31) but not for patients with BRCA1/2 mutations (hazard ratio, 0.74; 95% CI, 0.32 to 1.69). Conclusion The addition of bevacizumab may increase the pCR after standard neoadjuvant chemotherapy for patients with TNBC with BRCA1/2 mutations. In patients treated with anthracycline and taxane-based chemotherapy (with or without bevacizumab), pCR was a weaker predictor of DFS for BRCA1/2 mutation carriers than for patients without mutations.",
author = "Fasching, {P. A.} and S. Loibl and C. Hu and Hart, {S. N.} and H. Shimelis and R. Moore and C. Schem and H. Tesch and M. Untch and J. Hilfrich and M. Rezai and B. Gerber and Costa, {S. D.} and Blohmer, {J. U.} and T. Fehm and J. Huober and C. Liedtke and Weinshilboum, {R. M.} and L. Wang and Ingle, {J. N.} and V. Muller and V. Nekljudova and Weber, {K. E.} and B. Rack and M. Rubner and {von Minckwitz}, G. and Couch, {F. J.}",
year = "2018",
month = aug,
day = "1",
doi = "10.1200/JCO.2017.77.2285",
language = "English",
volume = "36",
pages = "2281--2287",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "22",

}

RIS

TY - JOUR

T1 - BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study

AU - Fasching, P. A.

AU - Loibl, S.

AU - Hu, C.

AU - Hart, S. N.

AU - Shimelis, H.

AU - Moore, R.

AU - Schem, C.

AU - Tesch, H.

AU - Untch, M.

AU - Hilfrich, J.

AU - Rezai, M.

AU - Gerber, B.

AU - Costa, S. D.

AU - Blohmer, J. U.

AU - Fehm, T.

AU - Huober, J.

AU - Liedtke, C.

AU - Weinshilboum, R. M.

AU - Wang, L.

AU - Ingle, J. N.

AU - Muller, V.

AU - Nekljudova, V.

AU - Weber, K. E.

AU - Rack, B.

AU - Rubner, M.

AU - von Minckwitz, G.

AU - Couch, F. J.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Purpose BRCA1/2 mutations are frequent in patients with triple-negative breast cancer (TNBC). These patients are often treated with primary systemic chemotherapy. The aim of this study was to analyze the effects of BRCA1/2 mutations on pathologic complete response (pCR) and disease-free survival (DFS) in a cohort of patients with TNBC treated with anthracycline and taxane-containing chemotherapy, with or without bevacizumab. Patients and Methods Germline DNA was sequenced to identify mutations in BRCA1 and BRCA2 in 493 patients with TNBC from the GeparQuinto study. The pCR rates were compared in patients with and without mutation, as well as in patients treated with and without bevacizumab. In addition, the influence of BRCA1/2 mutation status and pCR status on DFS was evaluated relative to treatment. Results BRCA1/2 mutations were detected in 18.3% of patients with TNBC. Overall, patients with mutations had a pCR rate of 50%, compared with 31.5% in patients without a mutation (odds ratio [OR], 2.17; 95% CI, 1.37 to 3.46; P = .001). The pCR rate among patients treated with bevacizumab was 61.5% for BRCA1/2 mutation carriers and 35.6% for those without mutations (OR, 2.90; 95% CI, 1.43 to 5.89; P = .004). pCR was a strong predictor of DFS for patients without BRCA1/2 mutations (hazard ratio, 0.18; 95% CI, 0.11 to 0.31) but not for patients with BRCA1/2 mutations (hazard ratio, 0.74; 95% CI, 0.32 to 1.69). Conclusion The addition of bevacizumab may increase the pCR after standard neoadjuvant chemotherapy for patients with TNBC with BRCA1/2 mutations. In patients treated with anthracycline and taxane-based chemotherapy (with or without bevacizumab), pCR was a weaker predictor of DFS for BRCA1/2 mutation carriers than for patients without mutations.

AB - Purpose BRCA1/2 mutations are frequent in patients with triple-negative breast cancer (TNBC). These patients are often treated with primary systemic chemotherapy. The aim of this study was to analyze the effects of BRCA1/2 mutations on pathologic complete response (pCR) and disease-free survival (DFS) in a cohort of patients with TNBC treated with anthracycline and taxane-containing chemotherapy, with or without bevacizumab. Patients and Methods Germline DNA was sequenced to identify mutations in BRCA1 and BRCA2 in 493 patients with TNBC from the GeparQuinto study. The pCR rates were compared in patients with and without mutation, as well as in patients treated with and without bevacizumab. In addition, the influence of BRCA1/2 mutation status and pCR status on DFS was evaluated relative to treatment. Results BRCA1/2 mutations were detected in 18.3% of patients with TNBC. Overall, patients with mutations had a pCR rate of 50%, compared with 31.5% in patients without a mutation (odds ratio [OR], 2.17; 95% CI, 1.37 to 3.46; P = .001). The pCR rate among patients treated with bevacizumab was 61.5% for BRCA1/2 mutation carriers and 35.6% for those without mutations (OR, 2.90; 95% CI, 1.43 to 5.89; P = .004). pCR was a strong predictor of DFS for patients without BRCA1/2 mutations (hazard ratio, 0.18; 95% CI, 0.11 to 0.31) but not for patients with BRCA1/2 mutations (hazard ratio, 0.74; 95% CI, 0.32 to 1.69). Conclusion The addition of bevacizumab may increase the pCR after standard neoadjuvant chemotherapy for patients with TNBC with BRCA1/2 mutations. In patients treated with anthracycline and taxane-based chemotherapy (with or without bevacizumab), pCR was a weaker predictor of DFS for BRCA1/2 mutation carriers than for patients without mutations.

U2 - 10.1200/JCO.2017.77.2285

DO - 10.1200/JCO.2017.77.2285

M3 - SCORING: Journal article

VL - 36

SP - 2281

EP - 2287

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 22

ER -